The Development of Pharmaceuticals Specific to Substance Use Disorders Has

question 12

Multiple Choice

The development of pharmaceuticals specific to substance use disorders has been delayed because

• A)those regions of the brain involved in the addictions are so widespread that no single pharmaceutical, or combination of pharmaceuticals, can work on every one.
• B)pharmaceutical companies view the demand as too limited to make the development of such medications worthwhile.
• C)the current generation of medications is sufficient to treat conditions associated with substance use disorders.
• D)there are new medications under development, which should revolutionize the treatment of substance use disorders.

---

Definitions:

Etiological Factors

Causes or contributing factors that lead to the development of a disease or psychological condition.

Autism Spectrum Disorder

Autism Spectrum Disorder is a developmental disorder characterized by difficulties in social interaction, communication, and by restricted and repetitive behavior patterns.

Phenylketonuria

A genetic disorder resulting in an inability to metabolize the amino acid phenylalanine, requiring a strict diet to prevent intellectual disability and other health problems.

PKU

Phenylketonuria, a rare inherited disorder that increases the levels of a substance called phenylalanine in the blood, requiring dietary management.